| Document |
Document Title |
|
WO/2022/097473A1 |
Nanoparticles including at least one amphiphilic molecule and a polymer compound having a structural unit represented by formula (1). (In formula (1), Ar1 and Ar2 represent a trivalent aromatic hydrocarbon ring group or a trivalent aro...
|
|
WO/2022/098014A1 |
The present invention relates to a composition for preventing or treating progeria through gene editing, the composition containing sgRNA to be hybridized with mRNA, which encodes progeria-causing progerin, and a gene encoding a Cas13 pr...
|
|
WO/2022/098619A1 |
The present disclosure relates to compositions and methods for cancer therapy. In particular, the present disclosure relates to compositions and methods for identifying subjects for treatment with cancer immunotherapy.
|
|
WO/2022/098143A1 |
The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredien...
|
|
WO/2022/097500A1 |
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
|
|
WO/2022/097634A1 |
A drug composition according to the present invention is characterized by having, as an active ingredient, at least one selected from the group consisting of FasL expression inhibitors, angiogenesis inhibitors, and STING agonists, and us...
|
|
WO/2022/098922A1 |
Described herein are chimeric proteins, specifically membrane-cleavable chimeric systems. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2022/098712A1 |
The present disclosure relates to the treatment of transfusion dependence in myelodysplastic syndrome (MDS). The present disclosure relates to methods of using novel biomarkers to treat transfusion dependence in an MDS patient in need th...
|
|
WO/2022/097794A1 |
The present invention relates to a composition for preventing, ameliorating or treating cachexia, comprising a complex extract of Salviae miltiorrhizae radix and Rhei radix et rhizoma, wherein the complex extract suppresses weight loss a...
|
|
WO/2022/090509A1 |
The present disclosure relates to the diagnosis, treatment and prophylaxis of age-related diseases, and increasing healthspan. Provided are methods of treating or preventing an age-related disease/condition, and in particular of treating...
|
|
WO/2022/092085A1 |
Provided is a pharmaceutical composition for treating tumors which is administered in combination with a PD-1 antagonist and contains 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin
-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H...
|
|
WO/2022/087666A1 |
A composition including 0.01-0.2% w/w retinol, 5-20% w/w alpha hydroxy acid, at least one emollient, at least one aqueous solvent, at least one emulsifying agent, at least one antioxidant, optionally at least one emulsion stabiliser, and...
|
|
WO/2022/092068A1 |
The present invention provides a small molecule drug that is an agonist to T cell receptor CD28. Also, the present invention develops a lead compound in drug development, said lead compound being capable of suppressing autoimmune disease...
|
|
WO/2022/090357A1 |
The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protectin...
|
|
WO/2022/092771A1 |
The present invention relates to a composition for treating herniated intervertebral disc or pain caused thereby, comprising a hydrogel patch, the composition having the effect of improving neurological grade before/after surgery, improv...
|
|
WO/2022/094615A1 |
Agonists of antisense activity are described. Agonists of antisense activity can be utilized in conjunction with antisense compounds to increase the antisense activity of the antisense compound. In some instances, a biological cell is co...
|
|
WO/2022/092775A1 |
The present invention relates to a pharmaceutical composition including ABT263 as an active ingredient for preventing and treating herniation of intervertebral discs, wherein ABT263 or Navitoclax can reduce expression of Mmp13, Adamts4, ...
|
|
WO/2022/092041A1 |
[Problem] The objective of the present invention is to provide an oral composition that can eliminate bacteria inside the oral cavity and that is capable of maintaining continuous moisturizing effect on the oral mucosa. [Solution] An ora...
|
|
WO/2022/093763A1 |
Disclosed herein are methods and compositions for modifying the Frailty Index Score of a patient by modifying the iAge and/or BMI of the patient. Also disclosed herein are methods for predicting the future Frailty Index Score of a patien...
|
|
WO/2022/090746A1 |
The present invention provides a NMT inhibitor for use in the prophylaxis or treatment of a senescence-associated disease or disorder.
|
|
WO/2022/092040A1 |
[Problem] The objective of the present invention is to provide an oral composition that exhibits anti-inflammatory action inside the oral cavity and that is capable of maintaining continuous moisturizing effect on the oral mucosa. [Solut...
|
|
WO/2021/248045A9 |
The disclosure provides for artificial signal peptides generated by systems and methods utilizing deep learning.
|
|
WO/2022/091736A1 |
Provided is a novel and/or improved means for improving the intestinal bacterial flora and/or suppressing the production of substances by intestinal putrefaction. This composition contains inulin and a resistant protein.
|
|
WO/2022/092310A1 |
The present invention provides a compound, etc. which has aldehyde dehydrogenase 2 (ALDH2) activating activity. Provided are a compound represented by formula (1), a pharmaceutically acceptable salt thereof, and a prodrug thereof. [In th...
|
|
WO/2022/090433A1 |
The present invention relates to the manufacture of a pellet formulation comprising an adsorbent and one or more excipients providing binder and disintegrating properties.
|
|
WO/2022/092124A1 |
Expression of matrix metalloprotease 1 is inhibited. A disclosed inhibitor of the expression of matrix metalloprotease 1 contains as active ingredient at least one selected from the group consisting of Saxifraga stolonifera, extracts of ...
|
|
WO/2022/089556A1 |
The present invention relates to a c-Myc protein inhibitor, a preparation method therefor, and a use thereof. The c-Myc protein inhibitor selectively inhibits a c-Myc protein, and therefore can be used in the prevention and treatment of ...
|
|
WO/2022/085322A1 |
This disclosure relates to a drug, treatment method, kit, and use, for treating pancreatic cancer in an individual by combining a PD-1/PD-L1 signal inhibitor, an IL-6 inhibitor, and at least one other antitumor agent.
|
|
WO/2022/085602A1 |
The purpose of the present invention is to provide a composition that is for TGR5 activation and that contains, as an active ingredient, a substance that has a TGR5 activation effect and that shows a high selectivity for TGR5. The presen...
|
|
WO/2022/084550A1 |
The present invention relates to compositions useful in the treatment or prevention of side effects of intestinal microbiota dysbiosis.
|
|
WO/2022/081297A1 |
Embodiments disclosed herein include nasal formulations and methods of use. In some embodiments, nasal formulations disclosed herein can include at least one agent comprising latanoprost, or pharmaceutically acceptable salt thereof; at l...
|
|
WO/2022/078310A1 |
Provided is a nucleic acid construct, comprising the following elements: a transposon 3' terminal repeat, a first polyA sequence, an insulator sequence having a transcription termination function, a transposon 5' terminal repeat, a trans...
|
|
WO/2022/082009A1 |
Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels. In some embodiments, the compounds disclosed ...
|
|
WO/2022/080250A1 |
Provided are (1) a propionic acid releaser containing PHB powder having a weight-average molecular weight of 10,000 or greater, (2) an acetic acid releaser containing PHB powder having a weight-average molecular weight of 10,000 or great...
|
|
WO/2022/079446A1 |
The present invention relates to treatments of bradykinin-mediated angioedema with a plasma kallikrein inhibitor, oral modified release pharmaceutical dosage forms comprising a plasma kallikrein inhibitor, and the uses of such dosage forms.
|
|
WO/2022/080529A1 |
The present invention relates to a pharmaceutical composition and a health functional food comprising alpha lipoic acid or a salt thereof, which alleviate damage to salivary glands to achieve an effect of preventing or treating hyposaliv...
|
|
WO/2022/080346A1 |
Provided is a novel pyrazoline derivative that can be used as a research reagent, a drug, and the like and can be synthesized at low cost by a simple reaction process. The novel pyrazoline derivative or a salt thereof is represented by G...
|
|
WO/2022/080473A1 |
The present inventors found that the indolinone compound of the present invention has excellent effect of activating nerve cells. The present inventors further found that the function mechanism of the effect of activating nerve cells is ...
|
|
WO/2022/080846A1 |
The present invention relates to a composition for treating fibrotic diseases, comprising 3,7-dimethoxyflavone or a derivative thereof, and more specifically, to a composition that can be applied to various fibrotic diseases by inhibitin...
|
|
WO/2022/081095A1 |
A method of treating an autoimmune disease in a patient comprising administering a therapeutically effective amount of a DHODH inhibitor or a pharmaceutically acceptable salt thereof. Also provided are formulations or compositions suitab...
|
|
WO/2022/075240A1 |
The present invention provides compounds that have a Pim-1 inhibitory activity. The present invention provides, inter alia, compounds with formula [I] and their pharmaceutically acceptable salts, pharmaceutical compositions containing ...
|
|
WO/2022/076620A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated disea...
|
|
WO/2022/075297A1 |
Provided is a novel food and drink which can continuously increase the lactic acid concentration in the blood. This food and drink contains a lactic acid compound and fructose, wherein the content of the lactic acid compound is 3-75 g ...
|
|
WO/2022/075444A1 |
A problem addressed by the present invention is to provide a low-molecular compound that has relatively high safety when ingested, that can be ingested orally, that can be produced relatively inexpensively, and that has anti-ferroptosis ...
|
|
WO/2022/075459A1 |
The purpose of the present invention is to increase the amount of oligonucleic acid transported into the cytoplasm by bringing about an efficient interaction of a cell uptake promoter with a target cell. An oligonucleic acid conjugate ac...
|
|
WO/2022/075337A1 |
The present invention provides an antibody or a fragment thereof that specifically binds to a 6-sulfosiallyl Lewis X-type sugar chain, and the bond requires the fucose, the sulfate group, and the sialic acid that form the 6-sulfosiallyl ...
|
|
WO/2022/076625A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...
|
|
WO/2022/075095A1 |
The present invention provides a novel glutathione production promoter. The present invention provides a glutathione production promoter containing as an active ingredient one or multiple crude drugs selected from the group consisting ...
|
|
WO/2022/075096A1 |
Provided is a novel RALDH2 expression enhancing agent. The present invention provides a RALDH2 expression enhancing agent containing, as an active ingredient, one or a plurality of components selected from the group consisting of querc...
|
|
WO/2022/075059A1 |
Provided is a novel sirtuin 1 activator. The present invention provides a sirtuin 1 activator containing as an active ingredient one or multiple crude drugs selected from the group consisting of lingonberry, echinacea, bee pollen, wolf...
|
